Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCX-013 + veledimex in localized scleroderma
NCT03740724Phase 2Terminated
- Sponsor
- Castle Creek Biosciences
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, Tissue Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FCX-013 in localized scleroderma, sponsored by Castle Creek Biosciences. Primary endpoint: Safety of FCX-013 Plus Veledimex. Started Dec 2019; status: terminated.
02
Drugs
FCX-013
03
Conditions
localized scleroderma
Beyond the preview
Go deeper on NCT03740724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740724.